Trial reportAnnals of surgical oncology2010
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial.
Trial report in Annals of surgical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00014612 (After Mapping Of The Axilla), which is not on this map. Cited by 84 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
After Mapping Of The Axilla: Radiotherapy Or Surgery
Who cites it
84 citing papers in PubMed, 4 syntheses or guidelines pooled it, 245 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of Sentinel Lymph Node Biopsy in Gastric Cancer, an Optimization of Imaging Protocol for Tracer Mapping.World journal of surgery · 2021Pooled it
- Feasibility and diagnostic performance of dual-tracer-guided sentinel lymph node biopsy in cT1-2N0M0 gastric cancer: a systematic review and meta-analysis of diagnostic studies.World journal of surgical oncology · 2017Pooled it
- Axillary treatment for operable primary breast cancer.The Cochrane database of systematic reviews · 2017Pooled it
- The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the ⁹⁹mTc-labeled nanocolloid human serum albumin standard of care.Clinical & experimental metastasis · 2012Pooled it
- Ultrasound-assisted carbon nanoparticle suspension mapping versus dual tracer-guided sentinel lymph node biopsy in patients with early breast cancer (ultraCars): phase III randomized clinical trial.The British journal of surgery · 2022Trial
- The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc(99) and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies.Breast cancer research and treatment · 2016Trial
- Trial
- Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance).Annals of surgery · 2015Trial
- Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.The Lancet. Oncology · 2014Trial
- Breast cancer sentinel lymph node mapping using near-infrared guided indocyanine green in comparison with blue dye.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Trial
- Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.The Lancet. Oncology · 2013Trial
- Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients.Annals of surgical oncology · 2012Trial
- Randomized, double-blind comparison of indocyanine green with or without albumin premixing for near-infrared fluorescence imaging of sentinel lymph nodes in breast cancer patients.Breast cancer research and treatment · 2011Trial
- Predicting ICG fluorescence uptake in laparoscopic lymphoma biopsy: the role of a 20 mm node size cut-off.Updates in surgery · 2026Article
- Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early-Stage Node-Negative HR+/HER2- Breast Cancer Undergoing Mastectomy.Annals of surgical oncology · 2026Article
- Sentinel lymph node detection in early-stage breast cancer - Are technetium-99m-nanocolloid and superparamagnetic iron oxide diagnostically equivalent procedures? A propensity score matched real world data analysis.Breast (Edinburgh, Scotland) · 2026Article
- Time-Dynamic AI Models to Predict Quality of Life in Patients With Breast Cancer: Development and Validation Study Using the EORTC BALANCE Cohort.Journal of medical Internet research · 2026Article
- Opportunities and challenges in pooling health-related quality-of-life data for prediction modeling in breast cancer across Europe: lessons from the EORTC BALANCE project.ESMO real world data and digital oncology · 2025Article
- Risk factors of sentinel lymph node metastasis in early-stage invasive breast cancer.Scientific reports · 2025Article
- Is Sentinel Lymph Node Biopsy Feasible in Multicentric Breast Cancer? A Case Report and Literature Review.Life (Basel, Switzerland) · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 11 institutions in 5 countries.
Funding
Abstract
backgroundThe randomized EORTC 10981-22023 AMAROS trial investigates whether breast cancer patients with a tumor-positive sentinel node biopsy (SNB) are best treated with an axillary lymph node dissection (ALND) or axillary radiotherapy (ART). The aim of the current substudy was to evaluate the identification rate and the nodal involvement.
methodsThe first 2,000 patients participating in the AMAROS trial were evaluated. Associations between the identification rate and technical, patient-, and tumor-related factors were evaluated. The outcome of the SNB procedure and potential further nodal involvement was assessed.
resultsIn 65 patients, the sentinel node could not be identified. As a result, the sentinel node identification rate was 97% (1,888 of 1,953). Variables affecting the success rate were age, pathological tumor size, histology, year of accrual, and method of detection. The SNB results of 65% of the patients (n = 1,220) were negative and the patients underwent no further axillary treatment. The SNB results were positive in 34% of the patients (n = 647), including macrometastases (n = 409, 63%), micrometastases (n = 161, 25%), and isolated tumor cells (n = 77, 12%). Further nodal involvement in patients with macrometastases, micrometastases, and isolated tumor cells undergoing an ALND was 41, 18, and 18%, respectively.
conclusionsWith a 97% detection rate in this prospective international multicenter study, the SNB procedure is highly effective, especially when the combined method is used. Further nodal involvement in patients with micrometastases and isolated tumor cells in the sentinel node was similar-both were 18%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.